CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 0.2%

CRISPR Therapeutics AG (NASDAQ:CRSP)’s stock price dropped 0.2% during mid-day trading on Monday . The stock traded as low as $54.37 and last traded at $54.95. Approximately 262,647 shares traded hands during trading, a decline of 86% from the average daily volume of 1,824,210 shares. The stock had previously closed at $55.05.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Wells Fargo & Company raised their price objective on CRISPR Therapeutics from $55.00 to $70.00 and gave the company an “equal weight” rating in a report on Thursday, February 22nd. Mizuho upped their price objective on CRISPR Therapeutics from $82.00 to $99.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. Royal Bank of Canada lifted their target price on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the stock a “sector perform” rating in a research report on Thursday, February 22nd. Morgan Stanley upped their price target on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the company an “underweight” rating in a research report on Monday, February 26th. Finally, Citigroup lifted their price target on shares of CRISPR Therapeutics from $88.00 to $89.00 and gave the stock a “buy” rating in a report on Thursday. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $76.29.

CRISPR Therapeutics Price Performance

The company’s fifty day moving average price is $72.96 and its 200 day moving average price is $63.67. The company has a market cap of $4.77 billion, a PE ratio of -28.30 and a beta of 1.76.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Wednesday, February 21st. The company reported $1.10 EPS for the quarter, beating the consensus estimate of $0.15 by $0.95. The firm had revenue of $201.20 million during the quarter, compared to analysts’ expectations of $148.72 million. The business’s revenue for the quarter was up 3253.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.41) EPS. On average, analysts forecast that CRISPR Therapeutics AG will post -6.24 EPS for the current year.

Insider Activity

In related news, CEO Samarth Kulkarni sold 50,000 shares of the firm’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $60.51, for a total transaction of $3,025,500.00. Following the completion of the sale, the chief executive officer now owns 187,377 shares in the company, valued at $11,338,182.27. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Samarth Kulkarni sold 50,000 shares of the firm’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $60.51, for a total transaction of $3,025,500.00. Following the completion of the sale, the chief executive officer now owns 187,377 shares in the company, valued at $11,338,182.27. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel James R. Kasinger sold 1,913 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total transaction of $152,408.71. Following the completion of the transaction, the general counsel now owns 57,371 shares of the company’s stock, valued at approximately $4,570,747.57. The disclosure for this sale can be found here. Insiders sold a total of 133,992 shares of company stock worth $9,157,835 over the last quarter. Insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On CRISPR Therapeutics

Large investors have recently modified their holdings of the company. Jump Financial LLC boosted its position in shares of CRISPR Therapeutics by 194.7% in the third quarter. Jump Financial LLC now owns 33,307 shares of the company’s stock valued at $1,512,000 after acquiring an additional 22,006 shares during the period. Baker Chad R bought a new position in shares of CRISPR Therapeutics in the third quarter valued at approximately $2,365,000. Capital Advisors Inc. OK lifted its position in CRISPR Therapeutics by 7.4% during the third quarter. Capital Advisors Inc. OK now owns 231,925 shares of the company’s stock valued at $10,527,000 after purchasing an additional 15,951 shares during the last quarter. Invesco Ltd. lifted its position in CRISPR Therapeutics by 1.5% during the third quarter. Invesco Ltd. now owns 136,123 shares of the company’s stock valued at $6,179,000 after purchasing an additional 2,061 shares during the last quarter. Finally, ARK Investment Management LLC lifted its position in CRISPR Therapeutics by 19.2% during the fourth quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company’s stock valued at $534,360,000 after purchasing an additional 1,372,986 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.